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Abstract
Objectives—HIV-infected women living in resource-constrained nations like Zambia are now
accessing antiretroviral therapy and thus may live long enough for HPV-induced cervical cancer to
manifest and progress. We evaluated the prevalence and predictors of cervical squamous
intraepithelial lesions (SIL) among HIV-infected women in Zambia.
Methods—We screened 150 consecutive, non-pregnant HIV-infected women accessing HIV/AIDS
care services in Lusaka, Zambia. We collected cervical specimens for cytological analysis by liquid-
based monolayer cytology (ThinPrep Pap Test®) and HPV typing using the Roche Linear Array®
PCR assay.
Results—The median age of study participants was 36 years (range 23-49 years) and their median
CD4+ count was 165/μL (range 7-942). The prevalence of SIL on cytology was 76% (114/150), of
which 23.3% (35/150) women had low-grade SIL, 32.6% (49/150) had high-grade SIL, and 20%
(30/150) had lesions suspicious for squamous cell carcinoma (SCC). High-risk HPV types were
present in 85.3% (128/150) women. On univariate analyses, age of the participant, CD4+ cell count,
and presence of any high-risk HPV type were significantly associated with the presence of severely
abnormal cytological lesions (i.e., high-grade SIL and lesions suspicious for SCC). Multivariable
logistic regression modeling suggested the presence of any high-risk HPV type as an independent
predictor of severely abnormal cytology (adjusted OR: 12.4, 95% CI 2.62-58.1, p=0.02).
Conclusions—The high prevalence of abnormal squamous cytology in our study is one of the
highest reported in any population worldwide. Screening of HIV-infected women in resource-
constrained settings like Zambia should be implemented to prevent development of HPV-induced
SCC.
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Each year, across the world, approximately 490,000 women are newly diagnosed and 274,000
women die from invasive cancer of the uterine cervix induced by oncogenic types of human
papillomavirus (HPV) [1-3]. The overwhelming majority of women affected by this completely
preventable disease live in resource-constrained nations where access to screening services is
limited or non-existent [2-5]. In these same settings, during the past decade, the HIV/AIDS
pandemic has overwhelmed the health care systems and had an enormous impact on women,
particularly those of reproductive age [6]. Of the nations in sub-Saharan Africa, Zambia has
one of the highest background prevalence rates of HIV (seroprevalence rate between 16% and
25%) as well as the second highest prevalence rate of invasive cervical cancer in the world
(prevalence of 61.1/100,000) [1,7]. Until recently, women living with HIV/AIDS in settings
like Zambia had very limited access to antiretroviral therapy and consequently had a very
limited survival period after being diagnosed with HIV. However, increasing numbers of
women are being linked to antiretroviral therapy treatment programs that have the potential to
improve their lifespan long enough for cervical cancer precursors to manifest and progress to
invasive cancer [8,9]. As such, HIV-infected women in resource-constrained environments are
now at heightened risk for the development and progression of HPV-induced cervical cancer
precursors to invasive cancer [10-13]. Thus, it is becoming increasingly necessary to provide
regular cervical cancer screening services for these women and to link screening and treatment
in such a manner that it ensures compliance.
Unfortunately, there are no clear and appropriate guidelines for screening HIV-infected women
who live in resource-constrained nations like Zambia, partly because of the lack of data
documenting the background prevalence of these lesions and the accuracy of screening tests
and protocols for these high-risk women.
With a goal to develop and evaluate the appropriateness of cervical cancer screening protocols
for HIV-infected women living in resource-constrained nations like Zambia, a pilot feasibility
study was undertaken among HIV-infected women attending the University of Zambia
Teaching Hospital, a tertiary referral center in Lusaka, Zambia. This paper reports the results
of the prevalence of cervical cytological abnormalities in these women and its relation to their
immunosuppressive state.
Methods
Study setting and participants
This study was approved by the Research Ethics Committee of the University of Zambia and
the Institutional Review Board of the University of Alabama at Birmingham. We offered
recruitment to 150 consecutive HIV-infected women attending the HIV-care clinic at the
University Teaching Hospital in Lusaka. After explanation of the study and clinical procedures,
all 150 women provided written informed consent administered in English, Bemba, or Nyanja.
Eligibility criteria included prior documented evidence of HIV infection (prior test records of
two positive rapid HIV 1/2 tests: Determine® and Capillus®), good mental and physical
condition, and current absence of acute illness. We excluded women who were pregnant
[menstrual history], had a history of previous diagnosis or treatment of cervical neoplasia, or
had undergone hysterectomy. After a clinical and pelvic examination, women showing signs
of sexually transmitted infections (e.g., cervicovaginal discharge) were counseled and treated
using World Health Organization guidelines for syndromic management and asked to return
to the clinic after 2 weeks for study screening and enrollment [14].
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In the clinical protocol, after administering the consent and confirming the eligibility, basic
sociodemographic data were collected using a structured questionnaire. A blood sample was
collected if no CD4+ cell count was documented in the previous three weeks. A trained
gynecologist conducted a physical and pelvic examination in all women. A trained nurse
midwife collected specimens for Pap smears from the ectocervix and endocervix using a plastic
Ayres spatula and cytobrush, respectively. The spatula and cytobrush were then vigorously
rinsed in vials containing PreservCyt® solution that were stored at room temperature for up to
2 weeks before being batch-transported to the United States for cytological analysis. After
cervical specimens were collected, visual inspection with acetic acid (VIA) test and
colposcopic exams were performed on all women by the nurse and gynecologist, respectively.
If indicated by colposcopy or cytology results, lesions were further evaluated by biopsy,
endocervical curettage, or loop electrical excision. Definitive surgical treatment
(hysterectomy; n=2) was provided as necessary.
Laboratory tests
Cytological analyses were undertaken in the United States after batch transport of specimens
from Zambia. Upon arrival, the specimen vials [prelabeled with a unique identifying number]
were logged and processed with a ThinPrep® 3000 processor [24-26]. All slides were stained
using the ThinPrep® Imaging System TP-3000 stain protocol. Slides had coverslips applied
on the “Sakura Tissue-Tek® GLAS Automated Glass Coverslipper” and allowed to dry prior
to review. All ThinPrep® samples were screened and diagnosed by a certified senior
cytotechnologist according to the 2001 Bethesda System guidelines [15]: normal [no squamous
cell abnormality], atypical squamous cells of undetermined significance (ASC-US), low-grade
squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL),
and suspicious for squamous cell carcinoma (SCC). All abnormal slides and 10% of normals
were subsequently reviewed by a board certified senior cytopathologist. We performed HPV
typing using the Roche Linear Array® polymerase chain reaction (PCR) from the residual fluid
in the specimen to test for the presence of genital HPV types [16]. The cytotechnician,
cytopathologist, and lab technician conducting HPV assays were all blinded to the clinical
profile and colposcopic and histological findings to ensure unbiased reporting.
Statistical analysis
Data entry was entered on site and confirmed in the United States. Statistical analysis was done
using SPSS14.0 for Windows™ (SPSS, Inc. Chicago, IL) and Design package of R Version
2.1.1. We conducted univariate and multivariable logistic regression to identify
sociodemographic and clinical characteristics predicting severe cytological abnormalities
(defined as either HSIL or SCC). We did not want to necessarily assume a linear relationship
between continuous predictors (age and CD4+ cell counts) and the log-odds of severe
cytological abnormalities, so these continuous variables were initially fit using restricted cubic
splines with 3 knots (using the default knot locations in the Design package). However, because
there was little evidence suggesting a non-linear relationship between CD4+ cell count and the
log-odds of severe cytological abnormalities (p>0.70), linearity was assumed for CD4+ cell
counts in the models presented here. Because of the limited sample size, we included in the
multivariable model only variables deemed a priori to be most scientifically important for
predicting the presence of severe cytological abnormalities.
Results
Between July and September 2004, 150 HIV-infected women were recruited in this cross-
sectional study. The median age was 36.0 years (range 23-49) and their median CD4+ cell
count was 165.0/μL (range 7-942). 76.3% (114/148) women reported receiving antiretroviral
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therapy whereas/although 22.9% (34/148) women had never accessed but were presently
seeking antiretroviral therapy. About a third of the women (56/150, 37.3%) were married and
cohabiting with their husband, just under a half of them were educated beyond high school
(71/150, 47.3%) and a majority (87/143, 60.9%) had a family income of less than US$100 per
month (∼US $3/day). Little over a third (57/149, 38.2%) of the women reported their age of
first sexual intercourse as less than 18 years and more than 85% of women reported between
one and five lifetime sexual partners (120/142, 82.7%). Of the 150 women who were evaluated
with cytological smears, only 10 (6.7%) had no abnormality whereas 140 (93.3%) were found
to have a squamous cell abnormality. SCC was reported in 30 (20.0%), HSIL in 49 (32.7%),
LSIL in 35 (23.3%), and ASC-US in 26 (17.3%) women on cytology (Fig. 1). In the univariate
analysis, between those with or without severe cytological abnormalities, we found no
statistical difference between educational status, marital status, having multiple (≥6) lifetime
sexual partners, and self-reported age of first sexual intercourse (≥< 18 years, self-reported
non-consistent/no condom use and nulliparity). However, women who had presence of high-
risk types of HPV were 9.2 (2.6-32.8) times more likely to have HSIL and SCC cytology than
women who did not have high-risk HPV types (p=0.001). Age was associated with the presence
of cytological abnormalities (p=0.021); the odds of having severe cytological abnormalities
were the highest at the median age of 36 (Fig. 2). CD4+ cell counts were linearly associated
with the presence of HSIL/SCC lesions (p=0.027) and the odds ratio for a 100-count decrease
in CD4+ count (e.g., the odds ratio for decrease from 300/μL to 200/μL) was 1.25 (95% CI of
1.03-1.54) (Fig. 3). Because of our sample size, we were limited in the number of variables we
could include in the multivariable analysis [47]. We chose to include age (using restricted cubic
splines with 3 knots), education, lifetime number of sexual partners (between 1 and 5, ≥6), age
of first sexual intercourse (<18 or ≥18 years), CD4+ cell count, and presence of high-risk HPV
types to develop a parsimonious multivariable model. Ten observations had missing data. On
multivariable modeling, presence of high-risk HPV types was the only significant predictor of
severe cytological abnormalities (adjusted OR: 12.4, 95% CI: 2.62-58.1, p=0.02) (Table 1).
Discussion
Nearly one in five HIV-infected women screened in our study had cytological evidence of
squamous cell carcinoma and one in three had cytological evidence suggestive of HSIL. This
high prevalence (>50%) of such severe cytologic abnormalities in women
immunocompromised by HIV is particularly alarming given the fact that approximately
12-30% of immunocompetent HIV-negative women with untreated HSIL are known to
progress to invasive cancer [17-19]. These results indicate the crucial importance of screening
HIV-infected women who live in resource-constrained settings, like those in Zambia, who are
now accessing antiretroviral therapy. The availability of cost-effective screening and treatment
for women who live in these environments is critical to reducing the morbidity and mortality
associated with cervical cancer.
Of the numerous cervical cancer screening studies that have been performed among HIV-
infected women in industrialized settings, most have found significantly higher rates of
preinvasive disease when compared to HIV-negative women [10-13,19-23]. In a review of
cervical cytology in HIV-infected women residing in such environments, the overall reported
prevalence of abnormalities ranged from 6% to 32%, with that of low-grade lesions ranging
from 11% to 19% and high-grade lesions from 7% to 15% [46]. In the same review, prevalence
rates of abnormal cervical cytology in HIV-infected women were reported to be as high as 38%
greater than those in HIV-negative women.
In general, most studies of cervical cytology among HIV-infected African women have been
based on opportunistic screening studies involving women attending outpatient clinics for
general medical care. Overall, screening results from such populations have revealed a 2- to
Parham et al. Page 4













3-fold increased risk of cellular abnormalities, and from such diverse sub-Saharan African
settings as Zimbabwe [25,26], Kenya [27,28], Senegal [29,30], Malawi [31,32], Rwanda
[33], Tanzania [34], Zaire [35], and South Africa [36 37]. The highest rates of cellular
abnormalities reported to date from Africa have come from investigations of commercial sex
workers in Zaire (27%) [35] and STI clinic attendees in Senegal (43%) [29]. In comparison,
the overall abnormal cytology rate of 93.8% and ≥HSIL rate of 53.1% in our study are perhaps
one of the highest reported in the literature for HIV-infected women.
The reasons for this high-prevalence could be partially attributed to the fact that the women in
our study were severely immunosuppressed (median CD4+ count 165/μL). The participants
were recruited from HIV-infected women attending the tertiary care hospital to receive
antiretroviral therapy, and to be eligible for such treatment they had to meet the criteria of
having a CD4+ count of <200/μL or have recently experienced some other AIDS defining
illness. Although a majority of our study participants (78.2%) were already taking antiretroviral
therapy, however, most had been taking it for less than 6 months. Nonetheless, settings such
as Zambia will encounter increasingly high numbers of such immunosuppressed women who
will now be accessing antiretroviral therapy. Providing cervical cancer screening and treatment
services linked to HIV/AIDS care is one possible avenue to provide this much needed
prevention intervention.
Another possible explanation for the high rate of severe cervical abnormalities detected in our
study participants is the very high sensitivity of monolayer liquid cytology [38-40], in
comparison to conventional cytology used in previously cited studies. Also, because the
cytological analysis was conducted in a sophisticated laboratory in the United States, it may
not be representative of developing country settings. Nonetheless, it highlights the hitherto
underestimated prevalence rate, mostly due to the lower sensitivity of conventional cytology
[41,42].
It is also important to note that most study participants were women living in marginalized
circumstances of the society, that is, most were inhabitants of peri-urban “compounds” that
are living quarters characterized by high unemployment rates, severe shortages of fresh water,
poor housing, inadequate sewage, and high rates of infectious diseases. All of the above are
widely prevalent conditions for the majority of HIV-infected women living in urban sub-
Saharan African cities like Lusaka. These same socioeconomic conditions prevent them from
accessing preventive and therapeutic clinical care, thereby increasing their vulnerability and
putting them at double jeopardy for both HIV/AIDS and cervical cancer.
As seen in our results, the risk of severe cytological abnormalities was highest around the
median age of our participants (36 years) with a downward trend both above and below the
median (Fig. 2). Because our sample was highly representative of HIV-infected women seeking
antiretroviral therapy in the public sector clinics in Zambia, it strongly suggests the critical
need for undertaking a concerted effort towards the provision of a cervical cancer screening
and treatment program that benefits the average woman accessing these clinics.
Presence of high-risk HPV was an independent predictor of HSIL and SCC on multivariable
modeling. These findings confirm the need for exploring the use of alternative screening
methods like HPV testing in conjunction with cytology or low-cost visual inspection based
methods, as a triage tool for the better management and adequate referral of these women to
colposcopy and/or treatment. The use of HPV testing among HIV-infected women has been
controversial [43-45]; however, the use of HPV testing in this high-risk population may offer
better outcomes if cost of testing falls within the range of donor-funded or government
supported activities. The crucial importance of investigations to study the natural history of
HPV-induced cervical neoplasia and the impact of antiretroviral therapy on the natural history
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of cervical neoplasia in these women is also highlighted through the findings of this preliminary
study.
Bilateral and multilateral donor assistance programs (e.g., Presidents Emergency Plan for
AIDS Relief, Global Fund) are improving the availability of antiretroviral therapy in resource-
constrained settings [8,9]. The findings in this report highlight the importance of linking
cervical cancer prevention services for HIV-infected women to antiretroviral therapy
programs. By so doing, we have the opportunity to reduce the burden of both HIV and cervical
cancer in impoverished settings where both diseases are most prevalent.
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Cytological results on ThinPrep Pap test among 150 HIV-infected women in Zambia. Note:
ASCUS: atypical squamous cells of undetermined significance; LSIL: low-grade squamous
intraepithelial lesions; HSIL: highgrade squamous intraepithelial lesions; SCC: suggestive of
squamous cell carcinoma.
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Relationship between age of participants and presence of severe cytological abnormalities.
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Relationship between CD4+ cell counts and presence of severe cytological abnormalities.
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